Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Study Identifier
P17-132
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Recruiting
Study Details
Medical Condition
Study Drug
N/A
Phase
N/A
Sex
Female & Male
Age
18+ years
Protocol Summary
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Study Locations
Location
Status
Location
Universitaetsklinikum St. Poelten /ID# 221152
Sankt Pölten, Lower Austria, Austria, 3100
Status
Recruiting
Location
Medizinische Universitaet Graz /ID# 221155
Graz, Styria, Austria, 8010
Status
Completed
Location
Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153
Salzburg, Austria, 5020
Status
Active, Not Recruiting
Location
Hanusch Krankenhaus /ID# 221151
Vienna, Austria, 1140
Status
Completed
Location
Stauferklinikum Schwaebisch Gmuend /ID# 201518
Mutlangen, Baden-Wurttemberg, Germany, 73557
Status
Completed
Location
Onkologische Praxis /ID# 201545
Stuttgart, Baden-Wurttemberg, Germany, 70174
Status
Completed
Showing {first} - {last} of {total} Results